MX2023006937A - Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos. - Google Patents

Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos.

Info

Publication number
MX2023006937A
MX2023006937A MX2023006937A MX2023006937A MX2023006937A MX 2023006937 A MX2023006937 A MX 2023006937A MX 2023006937 A MX2023006937 A MX 2023006937A MX 2023006937 A MX2023006937 A MX 2023006937A MX 2023006937 A MX2023006937 A MX 2023006937A
Authority
MX
Mexico
Prior art keywords
flt3
irak
compounds
compositions
inhibiting compounds
Prior art date
Application number
MX2023006937A
Other languages
English (en)
Spanish (es)
Inventor
Jan Susan Rosenbaum
Scott Bryan Hoyt
Craig Joseph Thomas
Daniel T Starczynowski
Maldonado Gabriel Gracia
Patrick Joseph Sutter
Gregory James Tawa
Chris James Finocchio
Original Assignee
Childrens Hospital Med Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Med Ct filed Critical Childrens Hospital Med Ct
Publication of MX2023006937A publication Critical patent/MX2023006937A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2023006937A 2020-12-15 2021-12-15 Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos. MX2023006937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063125654P 2020-12-15 2020-12-15
PCT/US2021/063567 WO2022132936A1 (en) 2020-12-15 2021-12-15 Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2023006937A true MX2023006937A (es) 2023-10-13

Family

ID=82058056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006937A MX2023006937A (es) 2020-12-15 2021-12-15 Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos.

Country Status (9)

Country Link
US (1) US12534469B2 (https=)
EP (1) EP4262802A4 (https=)
JP (1) JP2024500378A (https=)
CN (1) CN116887834A (https=)
AU (1) AU2021403015A1 (https=)
CA (1) CA3201690A1 (https=)
IL (1) IL303709A (https=)
MX (1) MX2023006937A (https=)
WO (1) WO2022132936A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
JP2025525322A (ja) * 2022-06-15 2025-08-05 チルドレンズ ホスピタル メディカル センター 多環式irak及びflt3阻害化合物並びにその使用
AU2024264188A1 (en) * 2023-04-28 2025-11-06 Kurome Therapeutics, Inc. Irak inhibitor free base, salts, and polymorphic forms thereof
WO2025029929A1 (en) * 2023-07-31 2025-02-06 Children's Hospital Medical Center Multi-cyclic irak1 and irak4 inhibiting compounds and uses thereof
WO2025137567A1 (en) * 2023-12-20 2025-06-26 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101324804B1 (ko) * 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
UY33304A (es) * 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
US10618903B2 (en) * 2015-06-24 2020-04-14 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
WO2017044623A1 (en) * 2015-09-09 2017-03-16 Lau Warren C Methods, compositions, and uses of novel fyn kinase inhibitors
US11542261B2 (en) * 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
SG11202005237SA (en) * 2017-12-15 2020-07-29 Pyramid Biosciences Inc 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
CN110835334B (zh) * 2018-08-16 2022-10-18 中国药科大学 吲哚取代唑类化合物及其用途

Also Published As

Publication number Publication date
JP2024500378A (ja) 2024-01-09
CN116887834A (zh) 2023-10-13
US20240124468A1 (en) 2024-04-18
EP4262802A1 (en) 2023-10-25
EP4262802A4 (en) 2024-11-13
WO2022132936A1 (en) 2022-06-23
AU2021403015A1 (en) 2023-08-03
US12534469B2 (en) 2026-01-27
CA3201690A1 (en) 2022-06-23
IL303709A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
MX2023006937A (es) Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos.
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
Luongo et al. Possible therapeutic effects of ozone mixture on hypoxia in tumor development
MX2024001193A (es) Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a sarcoma felino de mcdonough (flt3) y usos de estos.
ES2617689T3 (es) Combinación terapéutica que comprende un inhibidor de PLK1 y un agente antineoplásico
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
TW200740762A (en) Pyrazole compounds that modulate HSP90 activity
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
WO2021222542A8 (en) 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders
MX2009007777A (es) Terapia de combinacion que comprende romidepsina y bortezomib.
MX2023006938A (es) Compuestos inhibidores multicíclicos de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y usos de estos.
BR112023026452A2 (pt) Conjugados de fármacos peptídicos
WO2023245123A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023150601A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
IL197513A0 (en) Pyrazolopyrimidine derivatives and pharmaceutical compositions containing the same
UY30175A1 (es) Combinacion farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2020232191A8 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
WO2023250431A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2024163764A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
DOP2025000235A (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
MX2024005722A (es) Terapia de combinacion para el tratamiento del cancer de pulmon.
CR20240016A (es) Compuestos terapéuticos y procedimientos
BR112023017116A2 (pt) Composição farmacêutica combinada contendo inibidor de cdk4/6 e uso da mesma